Form 4: Hims & Hers CFO Exercises Options, Sells Shares

Hims & Hers Health, Inc.'s Chief Financial Officer, Oluyemi Okupe, executed planned stock option exercises and subsequent share sales on January 5, 2026.

Summary

• Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc., completed transactions involving Class A Common Stock on January 5, 2026.
• Exercised stock options to acquire 2,178 shares of Class A Common Stock at an exercise price of $5.01 per share.
• Exercised additional stock options to acquire 3,808 shares of Class A Common Stock at an exercise price of $11.53 per share.
• Sold 9,070 shares of Class A Common Stock at an average weighted price of $33.7875 per share, with individual sales ranging from $33.61 to $33.98.
• All reported stock option exercises and sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025.
• Following these transactions, direct beneficial ownership of Class A Common Stock stands at 91,617 shares, and indirect ownership is 7,853 shares held by the Oluyemi Okupe Separate Property Trust dtd 9-1-2021.
• Remaining derivative securities include 156,630 stock options exercisable at $5.01 and 44,746 stock options exercisable at $11.53.
• An additional 368 shares were acquired on November 20, 2025, under the Hims & Hers Health, Inc. 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercises and sales) conducted under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage their equity compensation. It does not contain information that would significantly alter the company's fundamental outlook or investor sentiment.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating transparent and planned insider activity.
• The exercise of stock options at significantly lower strike prices ($5.01 and $11.53) compared to the sale price ($33.7875) represents a profitable monetization of equity compensation for the insider.

Negatives

• The sale of 9,070 shares by a Chief Financial Officer, while common for monetizing vested options, could be perceived by some investors as a reduction in direct equity exposure.

Future Outlook

This filing is a report of past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This Form 4 filing details routine insider transactions by a company executive and does not provide information relevant to broader industry trends or competitive analysis. It reflects an individual's personal financial planning related to their equity compensation.

Corporate Governance

Related Party Transactions

• Indirect beneficial ownership of 7,853 shares of Class A Common Stock is held by the Oluyemi Okupe Separate Property Trust dtd 9-1-2021, which is a related party to the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a CFO, while a common practice for monetizing vested options, is generally viewed as a neutral event, especially when conducted under a pre-arranged 10b5-1 plan, which mitigates concerns about opportunistic selling. The overall impact on the company's share price is likely minimal given the routine nature and size of the transaction relative to the company's market capitalization.
• Employees: The mention of the Employee Stock Purchase Plan highlights a benefit available to employees for acquiring company stock.

Key Dates

Keywords

Hims & Hers Health Inc., HIMS, Oluyemi Okupe, Chief Financial Officer, CFO, Form 4, insider trading, stock options, share sale, 10b5-1 plan, beneficial ownership, equity securities